Form 8-K · Current Report · Filed 2025-08-07
Kenvue Reports Q2 2025 Results and Revises Outlook
Kenvue Inc. reported financial results for the second quarter of 2025, showing a net sales decrease of 4.0% and organic sales decline of 4.2%, impacted by volume decline and strategic price investments. Diluted EPS was $0.22, up from $0.03 in the prior year period. The company also revised its outlook for FY 2025, anticipating low-single-digit net sales and organic sales decline, and adjusted operating income margin decline. Additionally, Kenvue appointed Kirk Perry as Interim CEO and announced leadership changes, while continuing its strategic review.
- Filer
- Kenvue Inc. KVUE · NYSE
- Filed
- Accession
- 0001944048-25-000174
- CIK
- 0001944048
- Signal
- Low impactConsumer Defensive
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$21.44
Next session
-0.5%
Since filing
-10.3%
Latest close
$19.24
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from KVUE reporting the same item, with the next session's move:
Exhibits (1)
About Kenvue Inc.
Kenvue Inc. is a consumer healthcare and pharmaceutical company. It focuses on delivering a range of health-centric products, spanning hygiene, pain relief, and other wellness categories. With deep-rooted expertise in pharmaceuticals, Kenvue Inc. targets the health and wellness needs of individuals, providing both prescription and over-the-counter solutions. The company has established itself as a vital entity in the consumer health sector, significantly impacting community health standards and individual lives. Positioned in the pharmaceutical industry, Kenvue Inc. collaborates with healthcare providers to enhance its product reach and efficacy. Its broad portfolio includes well-known brands and formulations that are trusted globally by consumers seeking reliable health solutions. As a player in this sector, Kenvue Inc. contributes to the enhancement of public health, highlighting its prominence in both domestic and international markets.
Never miss another KVUE filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.